You are here: Industry Insights > Metacrine

News List

Metacrine Reports Positive Results from Phase 1 Trial of MET642 for NASH americanpharmaceuticalreview
January 06, 2021
Metacrine has reported preliminary results from its Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease.
Metacrine Announces MET409 Receives FDA Fast Track Designation for NASH Treatment americanpharmaceuticalreview
August 26, 2020
Metacrine announced the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET409, the company’s lead farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH).
Metacrine announces completion of series b financing biospectrumasia
December 08, 2017
Over the course of the past year, Metacrine has advanced its lead asset, MET409, an oral non-bile acid FXR agonist, into late stage IND-enabling studies
Metacrine Collaborates on FGF1 Variants for Glucose Lowering, Insulin Sensitivity americanpharmaceuticalreview
August 16, 2017
Metacrine has entered a collaboration with Novo Nordisk A/S to develop Fibroblast Growth Factor 1 (FGF1) variants for glucose lowering and insulin sensitization.